PuSH - Publication Server of Helmholtz Zentrum München

Abdelsalam, M.* ; Ibrahim, H.S.* ; Krauss, L.* ; Zessin, M.* ; Vecchio, A.* ; Hastreiter, S. ; Schutkowski, M.* ; Schneider, G.* ; Sippl, W.*

Development of pyrazine-anilinobenzamides as histone deacetylase HDAC1-3 selective inhibitors and biological testing against pancreas cancer cell lines.

Methods Mol. Biol. 2589, 145-155 (2023)
DOI PMC
Open Access Green as soon as Postprint is submitted to ZB.
Class I histone deacetylase (HDAC) enzymes are key regulators of cell proliferation and are frequently dysregulated in cancer cells. Here we describe the synthesis of a novel series of class-I selective HDAC inhibitors containing anilinobenzamide moieties as ZBG connected with a central (piperazin-1-yl)pyrazine moiety. Compounds were tested in vitro against class-I HDAC1, 2, and 3 isoforms. Some highly potent HDAC inhibitors were obtained and were tested in pancreatic cancer cells and showed promising activity. Moreover, we summarize how the growth-inhibitory effects of these compounds can be determined in murine pancreatic cancer cell lines.
Impact Factor
Scopus SNIP
Altmetric
0.429
0.570
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Anilinobenzamides ; Capping Group ; Class-i Histone Deacetylases Inhibitors ; Hdac ; Pancreas Cancer
Language english
Publication Year 2023
Prepublished in Year 2022
HGF-reported in Year 2022
ISSN (print) / ISBN 1064-3745
e-ISSN 1940-6029
Book Volume Title HDAC/HAT Function Assessment and Inhibitor Development
Quellenangaben Volume: 2589, Issue: , Pages: 145-155 Article Number: , Supplement: ,
Publisher Springer
Publishing Place Berlin [u.a.]
Reviewing status Peer reviewed
POF-Topic(s) 30201 - Metabolic Health
Research field(s) Genetics and Epidemiology
PSP Element(s) G-500600-004
Scopus ID 85140177259
PubMed ID 36255623
Erfassungsdatum 2022-10-26